171 related articles for article (PubMed ID: 32430019)
1. Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinoma.
Bharmal M; Nolte S; Henry-Szatkowski M; Hennessy M; Schlichting M
Health Qual Life Outcomes; 2020 May; 18(1):145. PubMed ID: 32430019
[TBL] [Abstract][Full Text] [Related]
2. Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma.
Bharmal M; Fofana F; Barbosa CD; Williams P; Mahnke L; Marrel A; Schlichting M
Health Qual Life Outcomes; 2017 Dec; 15(1):247. PubMed ID: 29273043
[TBL] [Abstract][Full Text] [Related]
3. Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial.
Lambert J; Marrel A; D'Angelo SP; Burgess MA; Chmielowski B; Fazio N; Gambichler T; Grob JJ; Lebbé C; Robert C; Russell J; Güzel G; Bharmal M
Patient; 2020 Aug; 13(4):457-467. PubMed ID: 32472503
[TBL] [Abstract][Full Text] [Related]
4. Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma.
Kaufman HL; Hunger M; Hennessy M; Schlichting M; Bharmal M
Future Oncol; 2018 Feb; 14(3):255-266. PubMed ID: 29219612
[TBL] [Abstract][Full Text] [Related]
5. Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences.
Kaufman HL; Dias Barbosa C; Guillemin I; Lambert J; Mahnke L; Bharmal M
Patient; 2018 Aug; 11(4):439-449. PubMed ID: 29512061
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.
Bharmal M; Nolte S; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Pusceddu S; Hanna GJ; Hassel JC; Kiecker F; Ellers-Lenz B; Bajars M; Güzel G; Nghiem P; Hunger M; Schlichting M; Henry-Szatkowski M; D'Angelo SP
Future Oncol; 2020 Sep; 16(27):2089-2099. PubMed ID: 32938212
[No Abstract] [Full Text] [Related]
7. Psychometric Properties of EQ-5D-5L Scoring Algorithms for the United Kingdom in Metastatic Merkel Cell Carcinoma.
Bharmal M; Hunger M; Schlichting M
Value Health; 2019 Oct; 22(10):1170-1177. PubMed ID: 31563260
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.
D'Angelo SP; Russell J; Lebbé C; Chmielowski B; Gambichler T; Grob JJ; Kiecker F; Rabinowits G; Terheyden P; Zwiener I; Bajars M; Hennessy M; Kaufman HL
JAMA Oncol; 2018 Sep; 4(9):e180077. PubMed ID: 29566106
[TBL] [Abstract][Full Text] [Related]
9. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
[TBL] [Abstract][Full Text] [Related]
10. Validity and performance of the Functional Assessment of Cancer Therapy-Bladder (FACT-Bl) among advanced urothelial cancer patients.
Degboe A; Ivanescu C; Rohay JM; Turner RR; Cella D
Support Care Cancer; 2019 Nov; 27(11):4189-4198. PubMed ID: 30825026
[TBL] [Abstract][Full Text] [Related]
11. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
Kaufman HL; Russell JS; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Milella M; Brownell I; Lewis KD; Lorch JH; von Heydebreck A; Hennessy M; Nghiem P
J Immunother Cancer; 2018 Jan; 6(1):7. PubMed ID: 29347993
[TBL] [Abstract][Full Text] [Related]
12. Reliability, validity, and change thresholds of the NCCN/FACT Bladder Symptom Index (NFBlSI-18) in patients with advanced urothelial cancer.
Peipert JD; Chang J; Li S; di Pietro A; Cislo P; Cappelleri JC; Cella D
Cancer; 2024 Jan; 130(1):31-40. PubMed ID: 37823532
[TBL] [Abstract][Full Text] [Related]
13. An empirical evaluation of the SF-12, SF-6D, EQ-5D and Michigan Hand Outcome Questionnaire in patients with rheumatoid arthritis of the hand.
Dritsaki M; Petrou S; Williams M; Lamb SE
Health Qual Life Outcomes; 2017 Jan; 15(1):20. PubMed ID: 28118833
[TBL] [Abstract][Full Text] [Related]
14. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel.
Cowey CL; Liu FX; Kim R; Boyd M; Fulcher N; Krulewicz S; Kasturi V; Bhanegaonkar A
Future Oncol; 2021 Jun; 17(18):2339-2350. PubMed ID: 33709776
[TBL] [Abstract][Full Text] [Related]
15. Psychometric validation of the French self and proxy versions of the PedsQL™ 4.0 generic health-related quality of life questionnaire for 8-12 year-old children.
Amedro P; Huguet H; Macioce V; Dorka R; Auer A; Guillaumont S; Auquier P; Abassi H; Picot MC
Health Qual Life Outcomes; 2021 Mar; 19(1):75. PubMed ID: 33663527
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study.
Fokkens W; Trigg A; Lee SE; Chan RH; Diamant Z; Hopkins C; Howarth P; Lund V; Mayer B; Sousa AR; Yancey S; Tabberer M;
J Patient Rep Outcomes; 2023 Jan; 7(1):4. PubMed ID: 36662344
[TBL] [Abstract][Full Text] [Related]
17. How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial.
Bharmal M; Guillemin I; Marrel A; Arnould B; Lambert J; Hennessy M; Fofana F
Orphanet J Rare Dis; 2018 Jun; 13(1):95. PubMed ID: 29914528
[TBL] [Abstract][Full Text] [Related]
18. Psychometric Properties of the Functional Assessment of Cancer Therapy-Neutropenia in Asian Cancer Patients With Chemotherapy-Induced Neutropenia.
Wang XJ; Wong CM; Chan A
J Pain Symptom Manage; 2016 Sep; 52(3):428-36. PubMed ID: 27392885
[TBL] [Abstract][Full Text] [Related]
19. Psychometric validation of anti-clot treatment scale and treatment satisfaction questionnaire for medication version II in Japanese patients with atrial fibrillation.
Watanabe-Fujinuma E; Banderas BF; Koretsune Y; Kumagai K; Uchiyama S; Yamashita T; Yasaka M; Akiyama S; Briere JB; Dickie G; Cano SJ
J Med Econ; 2019 Aug; 22(8):798-805. PubMed ID: 30995146
[No Abstract] [Full Text] [Related]
20. Validation study of the prototype of a disease-specific index measure for health-related quality of life in dementia.
Schölzel-Dorenbos CJ; Arons AM; Wammes JJ; Rikkert MG; Krabbe PF
Health Qual Life Outcomes; 2012 Sep; 10():118. PubMed ID: 23009579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
